U.S. Markets closed

Can You Imagine How Chuffed Admedus's (ASX:AHZ) Shareholders Feel About Its 102% Share Price Gain?

Simply Wall St

When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right business to buy shares in, you can make more than you can lose. Take, for example Admedus Limited (ASX:AHZ). Its share price is already up an impressive 102% in the last twelve months. On top of that, the share price is up 64% in about a quarter. In contrast, the longer term returns are negative, since the share price is 68% lower than it was three years ago.

View our latest analysis for Admedus

Given that Admedus didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last year Admedus saw its revenue shrink by 2.4%. So we would not have expected the share price to rise 102%. It just goes to show the market doesn't always pay attention to the reported numbers. It's quite likely the revenue fall was already priced in, anyway.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

ASX:AHZ Income Statement, January 13th 2020

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

It's good to see that Admedus has rewarded shareholders with a total shareholder return of 102% in the last twelve months. That certainly beats the loss of about 38% per year over the last half decade. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. You could get a better understanding of Admedus's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

We will like Admedus better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.